"A new generation of alternatives to monoclonal antibodies (mAbs) has entered the scene and may do the job better than their famous predecessors. These new therapeutics utilize the strengths of mAbs, such as high specificity and affinity and binding capability, while overcoming their weaknesses with smaller size, better delivery methods, easier and cheaper manufacturing, more diverse and customized immune responses and reduced risk of resistance. Learn what makes these next-generation relatives of mAbs different and exciting, as well as who is involved in the push for better protein therapeutics."

Objective1:Educate on new and exciting protein therapeutics in development.

Objective2:Provide specific information on what makes each of these therapeutics distinct.

Objective3:Bring a global perspective of companies involved in the push for alternatives.